Xolair 300 MG/2 ML autoinject 2ML
Ended Awarded
- Contract number
- SPE2DR26FDKR6
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $10,485
Award facts
- Contract value 100% obligated
- $10,484.64 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency issued a $10,484.64 delivery order to DMS Pharmaceutical Group Inc. on July 13, 2026, under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) for supply of Xolair 300 mg/2 mL autoinjector.
DMS Pharmaceutical Group Inc. is a woman-owned small business. Place of performance is Park Ridge, IL. The order carries a firm fixed price and an ultimate completion date of August 3, 2026.
Quick answers
Who was awarded contract SPE2DR26FDKR6?
SPE2DR26FDKR6 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on July 13, 2026.
How much is contract SPE2DR26FDKR6 worth?
The government has obligated $10,485 on SPE2DR26FDKR6.
Is contract SPE2DR26FDKR6 an order under another contract?
Yes. SPE2DR26FDKR6 is a delivery order under SPE2DR25D9144, an indefinite delivery contract.
Was contract SPE2DR26FDKR6 competed?
The extent of competition for SPE2DR26FDKR6 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award